Special Issue

Superoxide Dismutase Activity in Different Health Conditions

Message from the Guest Editors

Superoxide dismutase (SOD) is one of the most important enzymatic antioxidants, having the ability to neutralize superoxide due to catalytic disproportionation. SOD enzymes control the levels of reactive oxygen species, limiting their potential toxicity and regulating various aspects of cell life. The impact of SOD gene polymorphisms and/or alterations in SOD expression and activity have been observed in different pathological states including familial amyotrophic lateral sclerosis, inflammatory diseases, cystic fibrosis, chronic obstructive pulmonary disease, ischemia, as well as obesity and its metabolic and cardiovascular complications, but also in degenerative processes related to aging. The Special Issue "Superoxide Dismutase Activity in Different Health Conditions" will cover research topics and current review articles in this field.

Guest Editors

Dr. Marta Kepinska

Department of Biomedical and Environmental Analyses, Faculty of Pharmacy, Wroclaw Medical University, Borowska 211, 50-556 Wroclaw, Poland

Dr. Anna Prescha

Department of Food Science and Dietetics, Wroclaw Medical University, 50-556 Wrocław, Poland

Deadline for manuscript submissions

closed (31 October 2021)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/49691

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceutica

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals*.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

